The Clinical Utility of Amnioinfusion in Oligohydroamnios following PPROM.
- Author:
Mi Kyung KIM
1
;
Hye Sung WON
;
Myung Shin SHIN
;
So Ra KIM
;
Ji Yoon CHUNG
;
Pil Ryang LEE
;
In Sik LEE
;
Ahm KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
oligohydroamnios;
PPROM;
transabdominal amnioinfusion;
prophylactic amnioinfusion
- MeSH:
Apgar Score;
Birth Weight;
Chorioamnionitis;
Deceleration;
Dexamethasone;
Female;
Humans;
Incidence;
Medical Records;
Pregnancy;
Pregnant Women;
Rupture
- From:Korean Journal of Obstetrics and Gynecology
2001;44(2):364-368
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study was performed to evaluate the clinical utility of transabdominal prophylactic amnioinfusion on oligohydroamnios caused by preterm premature rupture of membrane(PPROM). METHODS: There were 59 singleton pregnant women with oligohydroamnios caused by PPROM who were treated by transabdominal amnioinfusion at the department of from March 1997 to December 1998. Nineteen pregnant women who underwent prophylactic amnioinfusion were designated as study group and 40 pregnant women who did not undergo prophylactic amnioinfusion were designated as control group. Clinical data were drawn from medical records, such as time interval from amnioinfusion to deliver, birth weight, incidence of variable deceleration, Apgar score at 1 minute, Apgar score at 5 minutes, and so on. Statistical analyses were performed by means of Student t test, Mann Whitney U-test, Fisher's exact test where appropriate. P value below 0.05 was considered significant. RESULTS: The median interval from amnioinfusion to delivery w as longer in study group than in control group (13.0 29.3 days vs. 5.0 13.0 days, p<0.05). The incidence of variable deceleration during labor in study group was 16% and that in control group was 43%(p<0.05). The incidence of Apgar score at 5 minutes below 7 was lower in study group than that in control group(39% vs. 43%, p<0.05). The incidence of respiratory distress syndrome was lower in study group than that in control group(16% vs. 83%, p=0.05) However, there were no significant difference in the incidence of respiratory distress syndrome between them who did not undergo dexamethasone treatment, in mode of delivery, birth weight, and incidence of chorioamnionitis between two groups. CONCLUSION: Transabdominal prophylactic amnioinfusion may have a positive role in the management of PPROM.
